Pharma Law Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Assaf Harofeh Medical Center, Zerifin, Israel

Studies from Israel and Japan add new findings to diabetes body of knowledge

Study 1: PPAR-gamma activation by rosiglitazone resulted in decreased manifestation of inflammatory hallmarks more strongly in a pregnant diabetic animal model.

According to a study from Israel, "The peroxisome proliferator activating nuclear receptors (PPAR) are activated in the context of inflammation, diabetes or normal pregnancy. Renal mesangial cells express PPAR-gamma which upon activation are capable of exerting anti-inflammatory effects."

J. Weissgarten and colleagues at the Assaf Harofeh Medical Center explained, "We investigated the effect of in vivo...

• View Other Issues of Pharma Law Weekly
  
• View Other NewsRx Publications